ReviewBioMed research international2020
Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges.
Review in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- The Correlation Between the Ratio of ALT to qHBsAg and the Recompensation of HBV-Related Cirrhosis Patients: A Retrospective Cohort Study Based on the Baveno VII Criteria.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Effect of viral hepatitis on type 2 diabetes: A Mendelian randomization study.World journal of diabetes · 2024Article
- Love-hate relationship between hepatitis B virus and type 2 diabetes: a Mendelian randomization study.Frontiers in microbiology · 2024Article
- [Current status and treatment strategies for liver injury before targeted immunotherapy for liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Review
- The regularity of nourishing-yin prescription for treating ascites due to hepatitis B cirrhosis based on data mining technology.Annals of translational medicine · 2023Article
- Ascites re-compensation in HBV-related first decompensated cirrhosis after anti-viral therapy.Frontiers in cellular and infection microbiology · 2022Article
- Differences in complications between hepatitis B-related cirrhosis and alcohol-related cirrhosis.Open medicine (Warsaw, Poland) · 2022Article
- Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study.BMJ open · 2021Article
- Hepatic Hydrothorax: A Comprehensive Approach to Diagnosis and Management.GE Portuguese journal of gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver-function decompensation or hepatocellular carcinoma (HCC) gradually appears after chronic hepatitis B progresses to cirrhosis. Effective antiviral treatment can significantly improve the long-term prognosis of decompensated patients, and some patients present recompensation of decompensated hepatitis B cirrhosis. At present, there are limited research data on the recompensation of decompensated hepatitis B cirrhosis. There is still controversy regarding the evaluation time, evaluation indicators, influencing factors, and long-term prognosis of recompensation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.